Madrigal Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Madrigal Pharmaceuticals has a total shareholder equity of $777.2M and total debt of $117.1M, which brings its debt-to-equity ratio to 15.1%. Its total assets and total liabilities are $1.1B and $296.1M respectively.
Key information
15.1%
Debt to equity ratio
US$117.09m
Debt
| Interest coverage ratio | n/a |
| Cash | US$998.63m |
| Equity | US$777.16m |
| Total liabilities | US$296.11m |
| Total assets | US$1.07b |
Recent financial health updates
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Recent updates
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Nov 02Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Financial Position Analysis
Short Term Liabilities: MDGL's short term assets ($1.1B) exceed its short term liabilities ($177.8M).
Long Term Liabilities: MDGL's short term assets ($1.1B) exceed its long term liabilities ($118.3M).
Debt to Equity History and Analysis
Debt Level: MDGL has more cash than its total debt.
Reducing Debt: MDGL's debt to equity ratio has increased from 0% to 15.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDGL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MDGL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.